To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Expression of ribosomal a… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients

Journal article
Authors Susanne Bram Ednersson
Martin Stenson
Mimmi Stern
G. Enblad
Henrik Fagman
Herman Nilsson-Ehle
Sverker Hasselblom
Per-Ola Andersson
Published in British Journal of Haematology
Volume 181
Issue 6
Pages 770-781
ISSN 0007-1048
Publication year 2018
Published at Institute of Biomedicine, Department of Pathology
Institute of Medicine
Pages 770-781
Language en
Links https://doi.org/10.1111/bjh.15259
Keywords DLBCL, proteomics, immunochemotherapy resistance, ribosomal, actin, rna-polymerase-i, cancer cells, cytoskeletal alterations, therapeutic, strategy, multiple-myeloma, drug-resistance, gastric-cancer, rho, gtpases, doxorubicin, proliferation, Hematology
Subject categories Hematology

Abstract

Diffuse large B cell lymphoma (DLBCL) patients with early relapse or refractory disease have a very poor outcome. Immunochemotherapy resistance will probably, also in the era of targeted drugs, remain the major cause of treatment failure. We used proteomic mass spectrometry to analyse the global protein expression of micro-dissected formalin-fixed paraffin-embedded tumour tissues from 97 DLBCL patients: 44 with primary refractory disease or relapse within 1year from diagnosis (REF/REL), and 53 who were progression-free more than 5years after diagnosis (CURED). We identified 2127 proteins: 442 were found in all patients and 102 were differentially expressed. Sixty-five proteins were overexpressed in REF/REL patients, of which 46 were ribosomal proteins (RPs) compared with 2 of the 37 overexpressed proteins in CURED patients (P=76x10(-10)). Twenty of 37 overexpressed proteins in CURED patients were associated with actin regulation, compared with 1 of 65 in REF/REL patients (P=14x10(-9)). Immunohistochemical staining showed higher expression of RPS5 and RPL17 in REF/REL patients while MARCKS-like protein, belonging to the actin network, was more highly expressed in CURED patients. Even though functional studies aimed at individual proteins and protein interactions to evaluate potential clinical effect are needed, our findings suggest new mechanisms behind immunochemotherapy resistance in DLBCL.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?